Clinical trials: Rosuvastatin
Healthy
A Clinical Trial to Evaluate the Effects of MK-4646 on Rosuvastatin in Healthy Participants (MK-4646-007)
Researchers are looking for new treatments for people living with HIV-1 (Human Immunodeficiency Virus Type 1). HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system.
- Trial name
- NCT07785830
- Testing
- Rosuvastatin, MK-4646
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cardiovascular Diseases, Hyperlipidemias
Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control
Fimasartan and Rosuvastatin for hypertension and dyslipidemia control
- Trial name
- FIMARO (NCT02913794)
- Where
- South Korea
- Volunteers
- 541 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertriglyceridemia, Hyperlipoproteinemia Type IV
Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients
The primary purpose of this trial is to determine if the treatment with rosuvastatin 10 and 20mg/day during 8 weeks in hypertriglyceridemic patients will reduce their triglyceride levels.
- Conditions
- Hypertriglyceridemia, Hyperlipoproteinemia Type IV, Hyperlipoproteinemia Type V, Hyperlipoproteinemia Type IIb
- Trial name
- NCT00473655
- Testing
- rosuvastatin
- Where
- 3 sites in Mexico
- Volunteers
- 334 people
- Sponsor
- AstraZeneca
Asthma
A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin
Leukotrienes are potent inflammatory molecules produced mainly by mast cells, eosinophils, monocytes/macrophage and neutrophils in response to allergic or inflammatory stimuli.
- Trial name
- NCT01411111
- Testing
- Rosuvastatin 10 mg, GSK2190915 30mg, GSK2190915 100mg
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypercholesterolaemia
Rosuvastatin Efficacy and Safety Evaluation in Hypercholesterolaemic Patients
This is a single-arm, phase IV, open-label, prospective, non interventional study to evaluate the efficacy, tolerability and safety of rosuvastatin administered for 24 weeks in approximately 900 Greek subjects with…
- Trial name
- RESEARCH (NCT00695539)
- Where
- 6 sites in Greece
- Volunteers
- 810 people
- Sponsor
- AstraZeneca
Healthy Volunteers
A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants
The purpose of this study is to evaluate the drug levels of CC-92480 after coadministration with rifampin and itraconazole and the drug levels of digoxin and rosuvastatin after coadministration with CC-92480 in healthy…
- Trial name
- NCT05389722
- Testing
- CC-92480, Rifampin, Itraconazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer
The primary purpose of this study is to determine the effect of multiple once daily administrations of enzalutamide on the pharmacokinetics of a single dose of digoxin (P-glycoprotein (P-gp) substrate) and rosuvastatin (breast…
- Trial name
- NCT04094519
- Testing
- enzalutamide, digoxin, rosuvastatin
- Where
- Moldova
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Endocrine System Diseases, Nutritional and Metabolic Diseases
Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia
To compare and evaluate the effects of LDL-C and Triglyceride (TG) control on the first dose Ezetimibe/Statin (Rosuvastatin 5 mg/Ezetimibe 10 mg) combination therapy compared to the average dose Statin (Rosuvastatin 10 mg)…
- Conditions
- Endocrine System Diseases, Nutritional and Metabolic Diseases, Diabetes Mellitus, Type 2, Dyslipidemias
- Trial name
- REMBRANDT (NCT04700436)
- Testing
- Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg), Suvast tablet 10 mg (Rosuvastatin 10 mg)
- Where
- 26 sites in South Korea
- Volunteers
- 146 people
- Sponsor
- Seoul National University Hospital
Drug Interactions
Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants
Researchers in this study want to learn how the study drug BAY1817080 interacts with another drug called rosuvastatin (brand name: Crestor) and affects the way the body absorbs, distributes and excretes rosuvastatin in healthy…
- Trial name
- NCT04252300
- Testing
- Rosuvastatin, Rosuvastatin + BAY1817080
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Hypertension, Dyslipidemias
Post Marketing Surveillance of Telostop TAB (Telmisartan/Rosuvastatin) for Evaluating the Safety and Efficacy
Post-marketing surveillance of Telostop TAB (Telmisartan/Rosuvastatin)
- Trial name
- NCT03742544
- Volunteers
- 600 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
ASCVD
High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients
This study will evaluate the efficacy and safety of high-intensity rosuvastatin and moderate-intensity rosuvastatin/ezetimibe in ASCVD patients.
- Trial name
- NCT03494270
- Testing
- Rosuvamibe, Monorova
- Where
- South Korea
- Volunteers
- 270 people
- Sponsor
- Yuhan Corporation
Drug Interaction Potentiation
Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin
This is a single-center, randomized, 2-period, 2-sequence, cross-over study.
- Trial name
- NCT01146483
- Testing
- Rosuvastatin, Pantoprazole
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Venous Thromboembolism, Deep Vein Thrombosis
Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)
Patients with cancer have a high risk of developing venous blood clots or thromboembolism (VTE). In an effort to target patients at highest risk of VTE for thromboprophylaxis (protective treatment for blood clots), numerous…
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Neoplasms
- Trial name
- DISOLVE (NCT01524653)
- Testing
- Rosuvastatin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Vermont
Hypertension, Hyperlipidemia
PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin
This is a Randomized, open-label, single-dose, 3-treatment, 3-period, 3-sequence crossover design.
- Trial name
- NCT02608242
- Testing
- YH22189, Twynsta 80/10mg, Crestor 20mg
- Where
- South Korea
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Participants
A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
The purpose of this study is to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult…
- Trial name
- NCT06416800
- Testing
- Digoxin, Rosuvastatin, Metformin
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Stable Coronary Artery Disease Undergoing PCI
Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty
Myocardial necrosis is relatively frequent after percutaneous coronary intervention and is associated with higher mortality during the follow-up.
- Trial name
- REMEDY (NCT02205775)
- Testing
- Atorvastatin, Rosuvastatin, Ezetimibe
- Where
- 6 sites in Italy
- Volunteers
- 280 people
- Sponsor
- G. d'Annunzio University
Atherosclerosis, Cardiovascular Disease
Is Augmentation of PORH by Rosuvastatin Adenosine-receptor Mediated?
Rationale: Statins form a class of drugs that is widely prescribed for hypercholesterolaemia, specifically to reduce the risk on atherosclerosis by lowering LDL-cholesterol.
- Trial name
- NCT00851175
- Testing
- rosuvastatin, caffeine
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Hypertension, Hyperlipidemia
The Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine
A randomized, open-label, multiple-dose, crossover study to investigate the pharmacokinetic drug interaction between rosuvastatin and telmisartan/amlodipine in healthy male volunteers
- Trial name
- NCT02387619
- Testing
- Rosuvastatin, Telmisartan/Amlodipine, Rosuvastatin and Telmisartan/Amlodipine
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Systemic Lupus Erythematosus, High LDL Cholesterol Level
Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level
Early statin therapy in SLE patients that have high cholesterol level and other atherosclerosis risk should reduce atherosclerosis and coronary artery events in later course of disease.
- Trial name
- NCT00866229
- Testing
- Rosuvastatin, Simvastatin
- Where
- Thailand
- Volunteers
- 140 people
- Sponsor
- Ramathibodi Hospital
Atherosclerosis, Inflammatory Activity in Coronary Arteries
Exploratory Study of Coronary Flow Reserve Measurements, a Non-Invasive Method for Coronary Function Measurements
The aim of this study is to investigate whether the non-invasive ultrasound method for assessment of coronary blood flow, transthoracic Doppler echocardiography-coronary flow reserve (TTDE-CFR), can be used to measure drug…
- Trial name
- NCT00783042
- Testing
- Rosuvastatin
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- AstraZeneca